Lukas M Carter
Overview
Explore the profile of Lukas M Carter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
617
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gajecki L, Lebedeva I, Liao Y, Ambriz D, Carter L, Kumpf M, et al.
J Nucl Med
. 2025 Feb;
PMID: 39978817
Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor frequently expressed in solid malignancies, such as glioblastoma and melanoma, with limited expression in healthy tissue, rendering it an ideal target...
2.
Marquis H, Schmidtlein C, de Nijs R, Minguez Gabina P, Gustafsson J, Kayal G, et al.
J Nucl Med
. 2025 Jan;
66(3):457-465.
PMID: 39884774
Accurate quantification in emission tomography is essential for internal radiopharmaceutical therapy dosimetry. Mean activity concentration measurements in objects with diameters less than 10 times the full width at half maximum...
3.
Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E, et al.
J Hematol Oncol
. 2025 Jan;
18(1):6.
PMID: 39806516
The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, and signaling molecules that interact to promote...
4.
Mack K, Bauer D, Carter L, Carrasco S, Atmane M, Viray T, et al.
Nucl Med Biol
. 2024 Nov;
140-141:108976.
PMID: 39615062
Background: Peritoneal metastasis with micrometastatic cell clusters is a common feature of advanced ovarian cancer. Targeted alpha therapy (TAT) is an attractive approach for treating micrometastatic diseases as alpha particles...
5.
Carter L, Ocampo Ramos J, Schuerrle S, Marquis H, Lassmann M, Bolch W, et al.
J Nucl Med
. 2024 Sep;
65(11):1808-1814.
PMID: 39327016
In nuclear medicine, estimating the number of radioactive decays that occur in a source organ per unit administered activity of a radiopharmaceutical (i.e., the time-integrated activity coefficient [TIAC]) is an...
6.
Haggstrom I, Carter L, Fuchs T, Kesner A
J Instrum
. 2024 Jun;
17(6).
PMID: 38938475
Aims: Clinical radiographic imaging is seated upon the principle of differential keV photon transmission through an object. At clinical x-ray energies the scattering of photons causes signal noise and is...
7.
Mack K, Samuels Z, Carter L, Viray T, Mandleywala K, Brooks C, et al.
J Nucl Med
. 2024 Mar;
65(4):580-585.
PMID: 38485271
Aberrantly expressed glycans on mucins such as mucin-16 (MUC16) are implicated in the biology that promotes ovarian cancer (OC) malignancy. Here, we investigated the theranostic potential of a humanized antibody,...
8.
Marquis H, Ocampo Ramos J, Carter L, Zanzonico P, Bolch W, Laforest R, et al.
J Nucl Med
. 2024 Feb;
PMID: 38388514
Y-microsphere radioembolization has become a well-established treatment option for liver malignancies and is one of the first U.S. Food and Drug Administration-approved unsealed radionuclide brachytherapy devices to incorporate dosimetry-based treatment...
9.
Sarrett S, Rodriguez C, Delaney S, Hosny M, Sebastiano J, Santos-Coquillat A, et al.
Mol Pharm
. 2024 Feb;
21(3):1402-1413.
PMID: 38331430
Despite decades of work, small-cell lung cancer (SCLC) remains a frustratingly recalcitrant disease. Both diagnosis and treatment are challenges: low-dose computed tomography (the approved method used for lung cancer screening)...
10.
Carter L, Zanzonico P
Mol Imaging Biol
. 2023 Nov;
26(1):17-28.
PMID: 37964036
Preclinical dosimetry is essential for guiding the design of animal radiopharmaceutical biodistribution, imaging, and therapy experiments, evaluating efficacy and/or toxicities in such experiments, ensuring compliance with ethical standards for animal...